Viaderma

Viaderma Days Payable Outstanding

The Days Payable Outstanding (DPO) of Viaderma (VDRM) as of Nov 4, 2026 is 32,775.51. In the previous year, Days Payable Outstanding (DPO) was 21,788.83 — a change of 50.42% (higher).

Days Payable Outstanding

32,775.51

YoY

50.42%

Last updated:

Days Payable Outstanding (DPO) of Viaderma is 2023 32,775.51 . Days Payable Outstanding (DPO) of Viaderma was 2022 21,788.83 . It decreases by 50.42% higher compared to the previous year.

The Viaderma Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2016
118.54 USD
Jan 1, 2017
172.81 USD
Jan 1, 2018
64.58 USD
Jan 1, 2019
36,541.46 USD
Jan 1, 2020
19,795.95 USD
Jan 1, 2021
4,611.68 USD
Jan 1, 2022
21,788.83 USD
Jan 1, 2023
32,775.51 USD
The Viaderma Days Payable Outstanding history
YEARDays Payable OutstandingYoY
32,775.51+50.42%
21,788.83+372.47%
4,611.68-76.70%
19,795.95-45.83%
36,541.46+56,479.99%
64.58-62.63%
172.81+45.79%
118.54-6.42%
126.67-94.93%
2,500.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Viaderma Stock analysis

What does Viaderma do? ViaDerma, Inc. generates revenue through the manufacturing and sale of pharmaceutical products, primarily its lead product Vitastem, a topical antibiotic brand. The company sells Vitastem directly to local medical practitioners and patients in clinics within the Los Angeles area, focusing on treating various skin conditions. Additionally, ViaDerma licenses its proprietary transdermal delivery technology, which enables rapid transfer of active ingredients through the skin for immediate localized therapy. The company also develops products in anti-aging skin care, pain management, hair-loss, and toenail fungus, though these are not yet commercialized. ViaDerma, Inc. operates through its subsidiary ViaDerma, II Inc., which supports the development and commercialization of its product portfolio. The company's revenue streams include direct sales of Vitastem to healthcare providers and patients, as well as licensing fees from its transdermal technology. The primary market segments are medical practitioners and patients seeking treatments for skin ailments in the Los Angeles region, with future growth potential in emerging product categories like anti-aging and hair-loss solutions. The company's business model centers on proprietary technology that differentiates its products, allowing for faster and more effective treatment delivery. Vitastem is the cornerstone of its current revenue, while the transdermal technology serves as a complementary asset for both current and future product lines. This approach enables ViaDerma to target specific medical needs with localized solutions, primarily in the Los Angeles market, while expanding into new therapeutic areas through its pipeline. Viaderma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Viaderma stock

Days Payable Outstanding (DPO) of Viaderma is 32,775.51 in 2023.

Days Payable Outstanding (DPO) of Viaderma changed from 21,788.83 to 32,775.51, representing a 50.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Viaderma since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Viaderma with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Viaderma

All Key Metrics — Viaderma